Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.

Inclusion Criteria:

1. Patients with early endometrial carcinoma with early FIGO clinical stage I-II (clinical examination, abdomino-pelvic MRI/Ultrasound - or CT scan if MRI notpossible - and endometrial biopsy or curettage), then stratification of therecurrence risk as defined by last European Society for Medical Oncology (ESMO)guidelines :

• Intermediate-risk endometrioid (type 1): FIGO stage IA/T1a grade 3, or IB grade 1 or 2

• Or High risk endometrioid (type 1) : FIGO stage IB/T1b grade 3, or II grade 1or 2 or 3

• Or High risk non endometrioid (type 2) : FIGO stages I-II

2. Without any suspicious pelvic, paraaortic, distant node at preoperative MRI

3. Age ≥ 18 years

4. Performance status (OMS) ≤ 2

5. No contraindication to surgery

6. Absence of known hypersensitivity to colloidal rhenium sulphide and technetium (nanocolloid) or one of its excipients, to human albumin preparations, to Nanocoll®and Rotop-nanoHSA® and their excipients, to injectable dyes (blue dye or indocyaninegreen if available) or one of their excipients, to triphenylmethane derivatives

7. Signed and dated informed consent

8. Effective contraception for patients with reproductive potential

9. Patient affiliated with a health insurance system

Exclusion Criteria:

1. Preoperative workup with :

• Previous hysterectomy (by nature, this trial cannot be offered as a secondarystaging procedure)

• non carcinoma (for example sarcoma, trophoblastic tumor)

• Low-risk endometrioid carcinoma as defined by the ESMO: 2009 FIGO stage IAgrade 1-2

• Metastatic disease at preoperative workup

• Suspicious adenopathy at preoperative workup

2. Pregnant and/or breastfeeding woman

3. No understanding of the trial

4. Patient deprived of liberty or in guardianship

5. Inexperience of the trial site in pelvic sentinel node detection